These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 9131489)

  • 21. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
    Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
    Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems.
    Salonen JS; Nyman L; Boobis AR; Edwards RJ; Watts P; Lake BG; Price RJ; Renwick AB; Gómez-Lechón MJ; Castell JV; Ingelman-Sundberg M; Hidestrand M; Guillouzo A; Corcos L; Goldfarb PS; Lewis DF; Taavitsainen P; Pelkonen O
    Drug Metab Dispos; 2003 Sep; 31(9):1093-102. PubMed ID: 12920164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential selectivity in carbamazepine-induced inactivation of cytochrome P450 enzymes in rat and human liver.
    Masubuchi Y; Nakano T; Ose A; Horie T
    Arch Toxicol; 2001 Nov; 75(9):538-43. PubMed ID: 11760814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development.
    Baranczewski P; Stańczak A; Sundberg K; Svensson R; Wallin A; Jansson J; Garberg P; Postlind H
    Pharmacol Rep; 2006; 58(4):453-72. PubMed ID: 16963792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
    Yan Z; Caldwell GW
    Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of drug-drug interactions: concepts and approaches.
    Weaver RJ
    Xenobiotica; 2001; 31(8-9):499-538. PubMed ID: 11569524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human hepatic cell cultures: in vitro and in vivo drug metabolism.
    Gómez-Lechón MJ; Donato T; Ponsoda X; Castell JV
    Altern Lab Anim; 2003; 31(3):257-65. PubMed ID: 15612868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro oxidative metabolism of cajaninstilbene Acid by human liver microsomes and hepatocytes: involvement of cytochrome p450 reaction phenotyping, inhibition, and induction studies.
    Hua X; Peng X; Tan S; Li C; Wang W; Luo M; Fu Y; Zu Y; Smyth H
    J Agric Food Chem; 2014 Oct; 62(43):10604-14. PubMed ID: 25272989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting clearance in humans from in vitro data.
    Obach RS
    Curr Top Med Chem; 2011; 11(4):334-9. PubMed ID: 21320062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal antibodies and multifunctional cytochrome P450: drug metabolism as paradigm.
    Gelboin HV; Krausz K
    J Clin Pharmacol; 2006 Mar; 46(3):353-72. PubMed ID: 16490812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
    Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
    Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An update on metabolism studies using human hepatocytes in primary culture.
    Gómez-Lechón MJ; Castell JV; Donato MT
    Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):837-54. PubMed ID: 18624674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes.
    Emoto C; Iwasaki K
    Xenobiotica; 2007 Sep; 37(9):986-99. PubMed ID: 17896325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition.
    Mukoyoshi M; Nishimura S; Hoshide S; Umeda S; Kanou M; Taniguchi K; Muroga H
    Xenobiotica; 2008 May; 38(5):496-510. PubMed ID: 18421623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the cytochrome P450 enzymes and enzyme kinetic parameters for metabolism of BVT.2938 using different in vitro systems.
    Baranczewski P; Edlund PO; Postlind H
    J Pharm Biomed Anal; 2006 Mar; 40(5):1121-30. PubMed ID: 16307862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction and inhibition of cytochrome P450 and drug-metabolizing enzymes by climbazole.
    Kobayashi Y; Suzuki M; Ohshiro N; Sunagawa T; Sasaki T; Oguro T; Tokuyama S; Yamamoto T; Yoshida T
    Biol Pharm Bull; 2002 Jan; 25(1):53-7. PubMed ID: 11824557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of human hepatocytes to investigate drug metabolism and CYP enzyme induction.
    Klieber S; Torreilles F; Guillou F; Fabre G
    Methods Mol Biol; 2010; 640():295-308. PubMed ID: 20645059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
    Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
    Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate.
    Naritomi Y; Terashita S; Kagayama A
    Xenobiotica; 2004 May; 34(5):415-27. PubMed ID: 15370958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [50 years of cytochrome P450. Drug metabolism - from past to present].
    Saussele T
    Med Monatsschr Pharm; 2014 Aug; 37(8):295-8. PubMed ID: 25158378
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.